Assessment of COVID-19 vaccine attitude in people with multiple sclerosis, its correlation with demographic factors, and fear of coronavirus: A cross-sectional survey

Background: Despite special global considerations which have been made to prioritize vaccination of people with multiple sclerosis (MS), some are reluctant to get vaccinated. This study was aimed to evaluate the attitude toward coronavirus disease-2019 (COVID-19) vaccine and its probable correlations. Methods: Considering the study objectives, two valid questionnaires including Fear of COVID-19 Scale (FCV-19S) and attitude questionnaires were administered pre and post COVID-19 vaccination among people with MS. Results: The questionnaires were administered among 349 people with MS pre and post vaccination. The mean age of participants was 38.78 ± 8.68 (range: 19 to 64) years. They all received the first dose of COVID-19 vaccine (Sinopharm). Although about 90% of participants felt satisfied after getting vaccinated and respected the preventive actions like social distancing and wearing face mask after vaccination, about 40% of them did not recommend vaccination to other patients. None of the demographic data was predictor of attitude score in COVID-19 vaccine and the only effective factor regarding fear of COVID-19 among people with MS was gender (P = 0.001). It was found that the more a patient’s fear score was, the more he/she felt satisfied after vaccination. Those patients who had got the influenza vaccine last year felt more satisfied with the vaccine and accepted the COVID-19 vaccine easier than others. Conclusion: This study revealed that there was an inverse correlation between fear of coronavirus and less trust in the vaccine in patients with MS. However, it should be mentioned that the patients felt more satisfied after COVID-19 vaccination.

[1]  M. Sahraian,et al.  COVID-19 vaccine hesitancy in Iranian patients with multiple sclerosis , 2022, Multiple Sclerosis and Related Disorders.

[2]  J. Vale,et al.  Opinions, beliefs and knowledge of people with multiple sclerosis on COVID-19 pandemic and vaccine , 2021, Multiple Sclerosis and Related Disorders.

[3]  Y. Broche-Pérez,et al.  Fear of COVID-19, problems accessing medical appointments, and subjective experience of disease progression, predict anxiety and depression reactions in patients with Multiple Sclerosis , 2021, Multiple Sclerosis and Related Disorders.

[4]  G. Stoker,et al.  Lack of Trust, Conspiracy Beliefs, and Social Media Use Predict COVID-19 Vaccine Hesitancy , 2021, Vaccines.

[5]  M. Sahraian,et al.  The Possible Direct Correlation between Cognitive Impairment and Fear of Catching COVID-19 among Patients with Multiple Sclerosis , 2021, Iranian journal of psychiatry.

[6]  M. Sahraian,et al.  Attitudes toward vaccination in patients with multiple sclerosis: A report from Iran , 2021, Multiple Sclerosis and Related Disorders.

[7]  M. Laubichler,et al.  Correlates of COVID-19 vaccine hesitancy in Austria: trust and the government , 2021, Journal of public health.

[8]  V. Shaygannejad,et al.  Fear of relapse, social support, and psychological well-being (depression, anxiety, and stress level) of patients with multiple sclerosis (MS) during the COVID-19 pandemic stage , 2021, Neurological Sciences.

[9]  Chris Baraniuk.  What do we know about China’s covid-19 vaccines? , 2021, BMJ.

[10]  Curtis J. Condon,et al.  Factors Associated with Willingness to be Vaccinated Against COVID-19 in a Large Convenience Sample , 2021, Journal of Community Health.

[11]  A. Chan,et al.  Vaccine Hesitancy in Patients With Multiple Sclerosis , 2021, Neurology: Neuroimmunology & Neuroinflammation.

[12]  R. Spain,et al.  COVID-19 vaccination willingness among people with multiple sclerosis , 2021, Multiple sclerosis journal - experimental, translational and clinical.

[13]  S. Bohlega,et al.  Managing multiple sclerosis in the Covid19 era: a review of the literature and consensus report from a panel of experts in Saudi Arabia , 2021, Multiple Sclerosis and Related Disorders.

[14]  Manuel Salavisa,et al.  Willingness to be vaccinated against COVID-19: An exploratory online survey in a Portuguese cohort of multiple sclerosis patients , 2021, Multiple Sclerosis and Related Disorders.

[15]  D. Centonze,et al.  COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies , 2021, CNS Drugs.

[16]  M. Sahraian,et al.  Attitude and Knowledge of Patients with Multiple Sclerosis (MS) About COVID-19 as Provided by Physicians , 2021, Archives of Neuroscience.

[17]  S. Hosseini,et al.  Fear and anxiety in patients with multiple sclerosis during COVID-19 pandemic; report of an Iranian population , 2021, Multiple Sclerosis and Related Disorders.

[18]  M. Sahraian,et al.  COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review , 2021, Multiple Sclerosis and Related Disorders.

[19]  C. Latkin,et al.  Trust in a COVID-19 vaccine in the U.S.: A social-ecological perspective , 2021, Social Science & Medicine.

[20]  R. Hunter,et al.  Fears for the future: A qualitative exploration of the experiences of individuals living with multiple sclerosis, and its impact upon the family from the perspective of the person with MS. , 2020, British journal of health psychology.

[21]  S. Wong,et al.  Influenza vaccine uptake, COVID-19 vaccination intention and vaccine hesitancy among nurses: A survey , 2020, International Journal of Nursing Studies.

[22]  M. Sahraian,et al.  Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis , 2020, Multiple Sclerosis and Related Disorders.

[23]  Y. Broche-Pérez,et al.  Correction to: Gender and Fear of COVID-19 in a Cuban Population Sample , 2020, International Journal of Mental Health and Addiction.

[24]  V. Milošević,et al.  Psychological status of patients with relapsing-remitting multiple sclerosis during coronavirus disease-2019 outbreak , 2020, Multiple Sclerosis and Related Disorders.

[25]  L. Gostin,et al.  The Dual Epidemics of COVID-19 and Influenza: Vaccine Acceptance, Coverage, and Mandates. , 2020, JAMA.

[26]  G. Tedeschi,et al.  Psychological consequences of COVID-19 pandemic in Italian MS patients: signs of resilience? , 2020, Journal of Neurology.

[27]  B. Padhi,et al.  Determinants of COVID-19 Vaccine Acceptance in Saudi Arabia: A Web-Based National Survey , 2020, Journal of multidisciplinary healthcare.

[28]  M. Sahraian,et al.  Knowledge regarding COVID-19 pandemic in patients with multiple sclerosis (MS): A report from Iran , 2020, Multiple Sclerosis and Related Disorders.

[29]  M. Sahraian,et al.  Evaluation of the Opinion of Patients With Multiple Sclerosis on the Outcomes of Catching COVID-19 and Its Effects on the MS Symptoms , 2020, Basic and clinical neuroscience.

[30]  A. Pakpour,et al.  The Fear of COVID-19 Scale: Development and Initial Validation , 2020, International Journal of Mental Health and Addiction.

[31]  J. Lechner-Scott,et al.  The COVID-19 pandemic and the use of MS disease-modifying therapies , 2020, Multiple Sclerosis and Related Disorders.

[32]  D. Ye,et al.  Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence , 2020, International Journal of Antimicrobial Agents.

[33]  M. Falautano,et al.  The first year after diagnosis: psychological impact on people with multiple sclerosis , 2017, Psychology, health & medicine.

[34]  E. Mohammadi,et al.  Confronting the Diagnosis of Multiple Sclerosis: A Qualitative Study of Patient Experiences , 2014, The journal of nursing research : JNR.

[35]  A. Moulin.  [French specificities in the history of vaccination. The end of an exception?]. , 2006, Revue d'epidemiologie et de sante publique.

[36]  T. Hemachudha,et al.  Neurological adverse events associated with vaccination , 2002, Current opinion in neurology.

[37]  L. Skovgaard.  Use and users of complementary and alternative medicine among people with multiple sclerosis in Denmark. , 2016, Danish medical journal.